Treat early to give your mHSPC patients the chance to live longer[1]

With ERLEADA® + ADT, the TITAN final analysis shows you can extend life and offer additional clinical benefits vs. placebo + ADT.[1]a

Dr and patient looking down
Three men icon
Shield icon

aPatients with severe angina, myocardial infarction, congestive heart failure, arterial or venous thromboembolic events, a history of or predisposition to seizure, or recent ventricular arrhythmias were excluded.[2]

Reduction in risk of death at almost 4 years[1]

An IPCW crossover analysis of OS was performed to adjust for the 208 patients in the placebo + ADT group that crossed over to ERLEADA® + ADT treatment at unblinding.[1]

Blue pie chart icon
Lime pie chart icon
ITT analysis
Crossover IPCW analysis
OS in the unadjusted patient population[1]b
OS unadjusted chart
Shield icon

Adapted from Chi KN, et al. 2021.

bOS and rPFS were dual primary endpoints of the TITAN study.[2]

What is a crossover-adjusted analysis and what can it show?

The IPCW model is frequently used to correct for bias of crossover patients in oncology trials.[3]

After unblinding, 208 patients without disease progression in the placebo + ADT group crossed over to receive open-label ERLEADA® + ADT. The median treatment duration with ERLEADA® + ADT in the crossover group was 15.4 months[1]
The IPCW method adjusts for placebo patients who cross over to receive active treatment, to provide a more accurate indication of efficacy of the treatment received[1]

Treat early with ERLEADA® + ADT to delay progression vs. placebo + ADT[1][2]

Treating early with ERLEADA® + ADT gives your mHSPC patients the chance to live longer.[2]

Improve rPFS
Prolong PFS2
Why PFS2?
Radiographic progression-free survival[2]c
Radiographic PFS chart
Shield icon

Adapted from Chi KN, et al. 2019.

crPFS: time from randomisation to first imaging-based documentation of progressive disease or death, whichever occurred first.[2]

Maintain the benefits of ERLEADA® + ADT through
to the next line of therapy[1]

Click below to see how you can give your patients a better chance of delaying progression with ERLEADA® + ADT vs. placebo + ADT[1][2]

Delay time to cytotoxic chemotherapy
Delay PSA progression
Delay castration resistance

Treat early with ERLEADA® + ADT to delay time to initiation of cytotoxic chemotherapy.[1]

Time to initiation of cytotoxic chemotherapy – secondary endpoint[1]
Time to chemotherapy chart
Adapted from Chi KN, et al. 2021.
Other secondary endpoints[1]

The secondary endpoints of time to pain progression, time to chronic opioid use, and time to skeletal-related event all favoured ERLEADA® + ADT over placebo + ADT.[1]

Treating early with ERLEADA® + ADT delays disease progression
in mHSPC patients and gives them the chance to live longer vs. placebo + ADT[1]

Click below to find out more about the clinical benefits with ERLEADA® + ADT:

ERLEADA® + ADT provides an additional treatment option

Give patients with mHSPC the opportunity for an additional treatment option upon disease progression[1][2]

Treat early in a broad range of mHSPC patients

Extend life across a broad range of mHSPC patients with ERLEADA® + ADT[1]

Maintain QoL

Push back on progression and maintain QoL in mHSPC[1]


ADT, androgen deprivation therapy. CI, confidence interval. EMA, European Medicines Agency. HR, hazard ratio. IPCW, inverse probability of censoring weighting. ITT, intention-to-treat. mCRPC, metastatic castration-resistant prostate cancer. mHSPC, metastatic hormone-sensitive prostate cancer. OS, overall survival. PFS2, second progression-free survival. PSA, prostate-specific antigen. QoL, quality of life. rPFS, radiographic progression-free survival.


Chi KN, et al. J Clin Oncol 2021 Apr 29:JCO2003488. doi: 10.1200/JCO.20.03488.
Chi KN, et al. N Engl J Med 2019;81:13–24.
Jönsson L, et al. Value Health 2014;17:707–713.
Oronsky B, et al. Neoplasia 2015;17:716–722.
CP-282954 - January 2022